J-Pharma Announces jRCT Registration of an Investigator-Initiated Trial of Nanvuranlat in Combination with Immune Checkpoint Inhibitors for Biliary Tract Cancer — Toward Combination Therapy with Immune Checkpoint Inhibitors in First-Line Treatment for Biliary Tract Cancer —

JPH034 Phase I Clinical Trial Registered on ClinicalTrials.gov

Notice of Availability of Webinar Recording Hosted by the Cholangiocarcinoma Foundation – Advancing Understanding of the Global Phase 3 Clinical Trial of Nanvuranlat –